p13-0541sc13ga.htm

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G/A
 
 
Under the Securities Exchange Act of 1934
 
(Amendment No. 3)*
 
Provectus Pharmaceuticals, Inc.
(Name of Issuer)
 
Common Stock, par value $0.001 per share
(Title of Class of Securities)
 
74373F100
(CUSIP Number)
 
December 31, 2012
(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
 
¨
Rule 13d-1(b)
x
Rule 13d-1(c)
¨
Rule 13d-1(d)
 
(Page 1 of 6 Pages)

______________________________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

 

 
 
 
CUSIP No.  74373F100
 
13G/A
Page 2 of 6 Pages



     
1
NAMES OF REPORTING PERSONS
Revelation Special Situations Fund Ltd
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5
SOLE VOTING POWER
- 0 -
6
SHARED VOTING POWER
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
7
SOLE DISPOSITIVE POWER
- 0 -
8
SHARED DISPOSITIVE POWER
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.22%
12
TYPE OF REPORTING PERSON
IV


 
    

 
 
 
CUSIP No.  74373F100
 
13G/A
Page 3 of 6 Pages



     
1
NAMES OF REPORTING PERSONS
Revelation Capital Management Ltd
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5
SOLE VOTING POWER
- 0 -
6
SHARED VOTING POWER
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
7
SOLE DISPOSITIVE POWER
- 0 -
8
SHARED DISPOSITIVE POWER
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.22%
12
TYPE OF REPORTING PERSON
IA



 
    

 
 
 
CUSIP No.  74373F100
 
13G/A
Page 4 of 6 Pages



     
1
NAMES OF REPORTING PERSONS
Chris Kuchanny
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5
SOLE VOTING POWER
- 0 -
6
SHARED VOTING POWER
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
7
SOLE DISPOSITIVE POWER
- 0 -
8
SHARED DISPOSITIVE POWER
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
816,134 shares of Common Stock
1,750,000 shares of Common Stock issuable upon exercise of Warrants
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.22%
12
TYPE OF REPORTING PERSON
IN



 
    

 
 
 
CUSIP No.  74373F100
 
13G/A
Page 5 of 6 Pages


This Amendment No. 3 (this "Amendment") amends the statement on Schedule 13G filed on June 1, 2010 (the "Original Schedule 13G"), as amended by Amendment No. 1 filed on February 11, 2011 and Amendment No. 2 filed on February 14, 2012 (the Original Schedule 13G as amended, the "Schedule 13G"), with respect to shares of common stock, par value $0.001 (the "Common Stock"), of Provectus Pharmaceuticals, Inc., a Nevada corporation (the "Company"). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Schedule 13G. This Amendment amends and restates Items 4 and 5 in their entirety as set forth below.

Item 4.
OWNERSHIP.
   
The information required by Items 4(a) - (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
     
   
The percentage set forth in Row (11) of the cover page for each Reporting Person is based on 113,701,071 shares of Common Stock issued and outstanding as of September 30, 2012, as disclosed in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on November 8, 2012 and assumes the exercise of the warrants reported herein.
 
The Fund and the Fund’s investment manager, Revelation, share voting and dispositive power over the shares held directly by the Fund. Mr. Kuchanny, as a principal of Revelation, shares voting and dispositive power over the shares reported by it. Each of Revelation and Mr. Kuchanny disclaims beneficial ownership of these securities (except to the extent of any pecuniary interest therein), and this report shall not be deemed an admission that either of them is the beneficial owner of such securities for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purposes.


Item 5.
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
   
 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following[X]


 
    

 
 
 
CUSIP No.  74373F100
 
13G/A
Page 6 of 6 Pages



SIGNATURES
 
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
 
DATED:  February 12, 2013

 
REVELATION SPECIAL SITUATIONS FUND LTD
   
 
/s/ Chris Kuchanny                
 
Name:     Chris Kuchanny
 
Title:       Chairman
   
   
 
REVELATION CAPITAL MANAGEMENT LTD
   
 
/s/ Chris Kuchanny               
 
Name:       Chris Kuchanny
 
Title:         Chairman and CEO
   
 
/s/ Chris Kuchanny               
 
CHRIS KUCHANNY